A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key regulatory decision by a U.S. Food and Drug Administration committee.

The introduction of new ... drugs (IMiDs) and proteasome inhibitors has brought a major shift in therapeutic paradigm in the treatment of newly diagnosed and refractory multiple myeloma (MM).

In 2003, bortezomib (Velcade; Millenium) became the first drug approved by the US FDA ... Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med.

While many treatments are available for multiple myeloma, frequent relapse in this type of blood cancer means patients need new treatment options that take different approaches to the disease.

(HealthDay News) — Genetic tests can show which patients with the blood cancer multiple myeloma should respond to targeted ...

Oncologist David Chung is taking on Northwell Health's newly established role of director of clinical research at its cancer ...

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at ...

Opens in a new tab or window Share on X ... in a phase III trial of relapsed or refractory multiple myeloma should smooth the way for the drug's reintroduction to the U.S. market.

Dec 18 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free ...

Multiple myeloma and AL amyloidosis are conditions ... Treatment with bortezomib may help improve outcomes. A combination of drugs may be more effective than single-drug treatment and help provide ...